Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) announced that Eric Dube, Ph.D., CEO, will present a corporate overview at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) announced that Eric Dube, Ph.D., CEO, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 a.m. PT. A live webcast will be available on the company's website, with an archived replay accessible for 30 days.
Travere Therapeutics focuses on developing therapies for rare diseases, collaborating with the community to understand patient needs and deliver impactful treatments.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +1.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference, on Thursday, January 12, 2023, at 11:15 a.m. PT.
A live webcast of the presentation will be accessible on the company’s website, ir.travere.com, under the “Events & Presentations” section, and an archived replay will be accessible for up to 30 days.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact:
Naomi Eichenbaum
Vice President, Investor Relations
IR@travere.com
888-969-7879
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.